Mostrando 9 resultados de: 9
Filtros aplicados
Subtipo de publicación
Article(9)
Publisher
Circulation(2)
Arquivos brasileiros de cardiologia(1)
CJC Open(1)
JAMA Cardiology(1)
Journal of the American College of Cardiology(1)
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
ArticleAbstract: Background: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmePalabras claves:Autores:Ali Z., Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Berwanger O., Bosch J.J., Choudhri S., Dans A.L., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Heenan L., Jolly S.S., Kontsevaya A., Loeb M., Lopes R.D., Pais P., Palileo-Villanueva L.M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopusApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
ArticleAbstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoBPalabras claves:acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitorsAutores:Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.Fuentes:scopusAlirocumab and cardiovascular outcomes after acute coronary syndrome
ArticleAbstract: BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemicPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Ducrocq G., Eapen Z., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Quintero K., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valdovinos P.C.M., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:scopusEffect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial
ArticleAbstract: Importance: Studies have found that patients at high cardiovascular risk often fail to receive evidePalabras claves:Autores:Almeida A.S., Amodeo C., Baldissera V., Baréa J.A.B., Barros E Silva P.G.D.M., Barroso S.L., Becke G.C.M., Bergo R.R., Berwanger O., Brandão Da Silva N., Campos V.B., Caron V., Conte D., Corrêa J.V.S., da Silva N.B., da Silva S.S., da Silva Serra K.C.C., da Silveira L., da Veiga V.d.F.N., Damiani L.P., Dantas J.M.M., de Assis R.M., de Barros E.F., de Figueiredo Neto J.A., de Moraes J.B.d.M.X., de Oliveira Silveira M.G., del Monaco M.I., do Brasil C.K.O.I., do Canto Filho M.J., do Carmo J.B., Domingues L.H., dos Santos E.V., dos Santos J.C., Duro L.N., Esper R.B., Esteves M.W., Feier A.P., Fernandes L.A.B., Filho J.A.S.B., Fonseca F.H., Fortes J.A.R., Gomes S.P.D.C., Gonçalves M.R., Gonzales B.P., Grezzana G.B., Guerra S.D., Guimarães H.P., Izar M.C., Jardim P.C.B.V., Kodama A., Kopittke L., Leães P.E., Lopes C.D., Lopes R.D., Lourenço S., Luiz R.O., Machline-Carrion M.J., Marcela G.d.O.A., Martin J.F.V., Martins G.L., Moraes M.J.D., Nakagawa R.H., Neto E.L., Neves M.F., Nobre F., Octavio Marques Pontes-Neto, Ormundo C., Orto F.T.C.D., Osugue R.K., Pauli C., Piegas L.S., Pinheiro S., Precoma D.B., Ramacciotti E., Ribeiro G.R., Rocha M.d.F., Sampaio B., Santo J.C.M.D.A., Santos J.Y., Santos P.D., SARAIVA J.O.S.E., Sehnem E., Silva A.L., Silva L.d.O., Silva L.P.W., Silva T.P., Silveira F.S., Sirena S.A., Soares R.M., Sousa A.L.L., Souza S.d.A.R., Stein A.T., Tobias J.S.P., Trama L.M., Vicente C.C., Wanderley F.F., Werle L., Woehl J., Ziebell J.V.Fuentes:scopusEffects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ArticleAbstract: Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovasculPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Colhoun H.M., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., DIaz R., Dilic M., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Loizeau V., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ArticleAbstract: Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for mPalabras claves:acute coronary syndrome, lipoprotein(a), low-density lipoprotein cholesterol, PCSK9 inhibitorAutores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Scemama M., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopus[First guidelines of the Brazilian Society of Cardiology on Cardiopulmonary Resuscitation and Cardiovascular Emergency Care].
ArticleAbstract:Palabras claves:Autores:Accorsi T.D., Almeida M.F.B., Andrade J.P., Araújo S., Arfelli E., Azeka E., Barbosa G.C., Barral T.C.N., Barreto A.C.P., Bernoche C., Brunório L., Canesin M.F., Cardoso L.F., Carvalho J.J.F.d., Cavalini J.F., Dallan L.A.P., Evaristo E.F., Farsky O.S., Favarato M.H., Feitosa-Filho G.S., Fernandes J.G., Ferreira F.G., Filgueiras Filho N.M., Franchi S.M., Franchin Neto C., Freitas G.R.d., Gagliardi R.J., Galas F.G., Gianotto-Oliveira R., Giovanini G.R., Gomes E.P., Gonçalves D.M., Gonçalves R.M., Gonzalez M.M.C., Guimarães H.P., Guimarães V.A., Guinsburg R., Hajjar L.A., Kalil Filho R., Lage S.G., Lima F.G., Lima V.C., Lisak S., Longo A.L., Lopes J.L., Lopes L.N.G.D., Lopes R.D., Machado C.A., Machado T.A.O., Malaque C.M.S., Mancuso F.J.N., Marques F.R.B., Martins S.O., Mattos F.R., Medeiros C.R., Miotto H.C., Miranda C.H., Miura N., Moraes Junior J.B.M.X., Nazima W., Octavio Marques Pontes-Neto, Oliveira Junior M.T., Oliveira-Filho J., Osawa E.A., Pavão M.L.R.C., Pazin-Filho A., Peixoto E., Piegas L.S., Pieri A., Pinheiro P.A.P.C., Pispico A., Polastri T.F., Quilici A.P., Rabelo M.M.N., Ramires J.A.F., Reis A., Ribeiro A.C., Sako Y.K., Sallai V.S., Sant'Ana D.G., Santos A.M., Schimidt A., Scudeler T.L., Shimoda M.S., Shimoda T., Silva R.C.G., Siqueira A.W., Sociedade Brasileira de Cardiologia , Souza M.F.S., Tanaka A.C.S., Tarasoutchi F., Teles J.M.M., Timerman A., Timerman S., Wen F.H., Xavier W.S.Fuentes:scopusRisk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
ArticleAbstract: Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapPalabras claves:acute coronary syndrome, alirocumab, dyslipidemias, GUIDELINEAutores:Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., DIaz R., Goodman S.G., Harrington R.A., Jukema J.W., Li Q.H., Lopes R.D., Louie M.J., Moriarty P.M., PATRICIO LOPEZ -JARAMILLO, Roe M.T., Schwartz G.G., Steg P.G., Szarek M., Vogel R., White H.D., Zeiher A.M.Fuentes:googlescopusThe Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
ArticleAbstract: Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trialsPalabras claves:Autores:Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Beresh H., Berwanger O., Bosch J.J., Chan N., Choudhri S., Dans A.L., DIaz R., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Jolly S.S., Kazmi K., Kontsevaya A., Lewis G., Loeb M., Lopes R.D., Nkeshimana M., Orlandini A., Pais P., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopus